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Abstract
VEGF induces normal or aberrant angiogenesis depending on its dose in the microenvironment around each producing cell 
in vivo. This transition depends on the balance between VEGF-induced endothelial stimulation and PDGF-BB-mediated 
pericyte recruitment, and co-expression of PDGF-BB normalizes aberrant angiogenesis despite high VEGF doses. We 
recently found that VEGF over-expression induces angiogenesis in skeletal muscle through an initial circumferential vascular 
enlargement followed by longitudinal splitting, rather than sprouting. Here we investigated the cellular mechanism by which 
PDGF-BB co-expression normalizes VEGF-induced aberrant angiogenesis. Monoclonal populations of transduced myoblasts, 
expressing similarly high levels of VEGF alone or with PDGF-BB, were implanted in mouse skeletal muscles. PDGF-BB 
co-expression did not promote sprouting and angiogenesis that occurred through vascular enlargement and splitting. However, 
enlargements were significantly smaller in diameter, due to a significant reduction in endothelial proliferation, and retained 
pericytes, which were otherwise lost with high VEGF alone. A time-course of histological analyses and repetitive intravital 
imaging showed that PDGF-BB co-expression anticipated the initiation of vascular enlargement and markedly accelerated 
the splitting process. Interestingly, quantification during in vivo imaging suggested that a global reduction in shear stress 
favored the initiation of transluminal pillar formation during VEGF-induced splitting angiogenesis. Quantification of target 
gene expression showed that VEGF-R2 signaling output was significantly reduced by PDGF-BB co-expression compared to 
VEGF alone. In conclusion, PDGF-BB co-expression prevents VEGF-induced aberrant angiogenesis by modulating VEGF-
R2 signaling and endothelial proliferation, thereby limiting the degree of circumferential enlargement and enabling efficient 
completion of vascular splitting into normal capillary networks despite high VEGF doses.
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Introduction
Coronary and peripheral artery diseases (CAD and PAD) 
remain the major causes of morbidity and mortality in 
Western countries, despite current medical and surgical 
options [1]. Therapeutic angiogenesis aims at restoring 
the blood supply in ischemic tissues by delivering factors 
that control vascular growth and is an attractive strategy 
to improve treatment of these disabling and often fatal 
conditions. Vascular Endothelial Factor-A (VEGF) is the 
master regulator of vascular growth both in development 
and tissue repair [2] and is therefore the key molecular 
target for therapeutic angiogenesis [3]. However, clinical 
trials of VEGF gene delivery have yielded disappointing 
results, despite the clear biological activity of the factor 
[3, 4]. There is therefore a clear need to better understand 
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the mechanisms of VEGF-induced angiogenesis, particu-
larly under therapeutically relevant conditions of factor 
delivery.
The best-studied mechanism of angiogenesis is sprout-
ing, whereby specialized endothelial tip cells sense a 
VEGF gradient and migrate towards its source to invade 
surrounding tissue, followed by proliferating stalk cells 
that form the new vessel lumen [2]. On the other hand, 
expansion of already formed vascular networks can also 
take place by the alternative mechanism of splitting 
angiogenesis, which entails the formation of intraluminal 
endothelial pillars that split pre-existing vessels longi-
tudinally to form new ones [5]. However, the regulation 
of splitting angiogenesis is little studied and still poorly 
understood. In order to investigate how VEGF gene deliv-
ery regulates vascular growth in the therapeutic target tis-
sue of skeletal muscle, we have previously developed a 
highly controlled gene delivery platform, based on mono-
clonal populations of transduced myoblasts that ensure 
homogeneous expression of specific doses or combinations 
of angiogenic factors [6, 7] and we found that (1) VEGF 
induces either physiological microvascular networks or 
aberrant angioma-like structures depending on its dose 
localized in the microenvironment around each producing 
cell in vivo [7]; (2) at the doses required for functional 
ischemia relief [8], VEGF induces muscle angiogen-
esis essentially without sprouting and rather by vascular 
splitting [9]; and (3) the switch from normal to aberrant 
angiogenesis does not depend exclusively on VEGF dose, 
but rather on the balance between endothelial stimulation 
by VEGF and pericyte recruitment by Platelet-Derived 
Growth Factor-BB (PDGF-BB), such that PDGF-BB co-
delivery ensures normal and functional microvascular 
growth despite high or uncontrolled VEGF expression 
[6, 10]. VEGF-induced angiogenesis in skeletal muscle 
entailed two distinct phases, namely, an initial stage of cir-
cumferential vascular enlargement during the first 4 days, 
followed by longitudinal splitting that is complete within 
day 7 [9].
We have previously established that endogenous PDGF-
BB is required to ensure physiological angiogenesis by 
moderate VEGF doses and its co-delivery can normalize 
angiogenesis by high levels of VEGF, expanding its thera-
peutic window [6, 10]. However, how this happens and 
whether PDGF-BB may regulate splitting angiogenesis has 
not been studied. Here, we sought to investigate the cel-
lular mechanisms by which PDGF-BB regulates the VEGF 
dose-dependent switch from normal to aberrant angiogen-
esis in skeletal muscle. We found that PDGF-BB prevents 
pericyte loss induced by high VEGF and regulates split-
ting angiogenesis by reducing the activation of VEGF-R2 
signaling and endothelial proliferation, thereby limiting 
the degree of initial vascular enlargement and enabling 
successful splitting regardless of VEGF dose.
Results
PDGF‑BB accelerates splitting angiogenesis by high 
VEGF
First we sought to determine the cellular mechanism by 
which PDGF-BB co-expression prevents VEGF-induced 
aberrant angiogenesis, i.e., whether by switching vascular 
growth from splitting to sprouting, or rather modulating 
the initial morphogenic events of VEGF-induced vascular 
enlargement and splitting. In order to rigorously control the 
in vivo dose of VEGF and PDGF-BB, we took advantage of 
well characterized libraries of monoclonal populations of 
retrovirally transduced murine myoblasts that we previously 
generated and that homogeneously express specific levels 
of  VEGF164 alone (V clones) or together with PDGF-BB 
at a fixed ratio of 1:3 (VIP clones), or PDGF-BB alone (P 
clones) [6, 7, 11]. As every cell in each monoclonal popula-
tion has the same copy number and genomic integration sites 
of the retroviral vector, they all secrete the same amount 
of the factors and therefore the use of such populations 
enables the control of their dose in the microenvironment 
around each cell [6, 7]. Myoblast clones were selected that 
secrete a high level of VEGF alone (Vhigh, causing aberrant 
angiogenesis) or together with PDGF-BB  (VIPhigh, causing 
instead its normalization into physiological capillary net-
works) [6] and implanted them into limb muscles of mice 
(tibialis anterior and gastrocnemius). Myoblasts that do not 
express either VEGF or PDGF-BB were used as control 
(ctrl). The kinetics of initial vascular morphogenesis was 
analyzed 2, 3, 4, and 7 days after cell implantation by cor-
rosion casting, the gold standard to identify intussusception 
[12], and immunofluorescence confocal microscopy, which 
effectively detects endothelial sprouting. Control myoblasts 
did not induce angiogenesis at any time point (Fig. 1a–d, 
ctrl). As previously observed [9], after 2 days high levels 
of VEGF alone did not yet perturb the pre-existing vessels 
(Fig. 1a, Vhigh) and enlarged vascular structures appeared 
by 3 and 4 days (Fig. 1b, c, Vhigh). Vessel casts of these 
structures were pierced by numerous small holes (Fig. 1b, 
c, Vhigh, and arrowheads in Fig. 1e, g), which are the hall-
mark of the initial formation of transluminal pillars [5, 9]. 
Again consistently with previous observations, by 7 days 
signs of pillar formation had disappeared from the aberrant 
bulbous angioma-like structures induced by high VEGF 
(stars in Fig. 1d, Vhigh). On the other hand, co-delivery of 
PDGF-BB caused vascular enlargements already by 2 days, 
whose casts also showed signs of numerous intralumi-
nal pillars being formed (Fig. 1a,  VIPhigh and f). By day 
Angiogenesis 
1 3
3, vascular casts displayed both pillar formation and evi-
dence of longitudinal splitting (Fig. 1b,  VIPhigh and dashed 
rectangle in Fig. 1h) into new vascular segments. Surpris-
ingly, with co-delivery of high levels of VEGF and PDGF-
BB vascular remodeling was already complete by 4 days, 
yielding networks of normal capillaries (Fig. 1c,  VIPhigh), 
which were similar to and denser than networks visible in 
control samples (Fig. 1a–d, ctrl), with no further change in 
morphology by day 7 (Fig. 1d,  VIPhigh). The occurrence of 
intussusceptive angiogenesis was quantified by measuring 
the numerical density of pillars, defined as the total num-
ber of pillars per  mm2 of vascular surface area. Since VIP 
conditions displayed an anticipated and faster kinetics of 
vascular remodeling, we sought to compare equivalent bio-
logical stages of vessel development rather than the same 
time points. Therefore, we defined two different stages to 
Fig. 1  PDGF-BB co-expression anticipates vascular enlargement 
formation and accelerates vascular splitting: clonal populations of 
transduced myoblasts expressing high levels of VEGF alone (Vhigh 
myoblast) or co-expressed together with PGF-BB  (VIPhigh myoblast) 
and control myoblasts (ctrl) were implanted in TA and GC muscles of 
SCID mice. a–h Vascular corrosion casts of the entire legs were per-
formed at 2, 3, 4, and 7 days post-implantation. The time point labels 
(2, 3, 4, and 7 days) refer to all images in each column delimited by 
the red vertical lines. The white rectangles in panels b-Vhigh, c-Vhigh, 
a-VIPhigh, and b-VIPhigh are shown at higher magnification in e–h. 
White arrowheads: small indentations and holes indicative of trans-
luminal tissue pillar formation. Dash rectangle in h vascular splitting 
after transluminal pillar fusion. Asterisks in d-Vhigh angioma-like 
structures devoid of further signs of pillar formation. n = 3 independ-
ent samples per group, per time point. a–d Scale bars = 100 µm, e–h 
Scale bars = 25  µm. i Quantification of the relative numerical pillar 
density (number of pillars per vessel area) at equivalent biological 
stages; data points represent the means of individual measurements 
in each sample, while bars show the overall mean ± SEM. n = 3 inde-
pendent samples per group, per time point
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represent equivalent biological states (Fig. 1e–h), i.e., stage 
1 to be the first day of vascular enlargement (corresponding 
to day 3 for Vhigh and day 2 for  VIPhigh conditions) and stage 
2 to be the second day of remodeling (corresponding to day 
4 for Vhigh and day 3 for  VIPhigh). As shown in Fig. 1i, quan-
tifications confirmed the abundant and similar pillar forma-
tion during the two different stages in both conditions (day 
3 Vhigh = 1345 ± 195 vs. day 2  VIPhigh = 1091 ± 131, p = n.s.; 
day 4 Vhigh = 868 ± 74 vs. day 3  VIPhigh = 843 ± 241, p = n.s.), 
suggesting that PDGF-BB co-delivery did not influence the 
timing and frequency of pillar formation.
On the other hand, corrosion casting only shows the 
lumen of vascular structures and is not optimal to detect 
endothelial sprouts, which are devoid of lumen in their 
migrating tips [13]. Therefore, we investigated the evi-
dence for sprout formation also by confocal microscopy 
and 3D reconstruction of thin optical sections after immu-
nostaining for endomucin, which homogeneously stains 
all endothelial structures, including the filopodia on 
sprouting tip cells, and laminin, which labels the basal 
lamina and defines the external boundary of vessels [9]. 
Careful analysis of the enlarged vessel walls revealed 
that the endomucin-positive cells of enlarged vascular 
structures were completely contained within the respec-
tive basal lamina and no endothelial extensions could be 
seen protruding outside of it, thereby confirming the lack 
of abluminal sprouting (Fig. 2a–c, d–f). Remarkably, in 
the enlarged vascular structures it was possible to observe 
pillar formation both as small holes in the endomucin-
positive endothelium (arrows in Fig. 2a, d, high-magni-
fication panels), compatible with those displayed in the 
corrosion casts, as well as endothelial filopodial exten-
sions (arrowheads in Fig. 2d, high-magnification panel) 
projecting inside the vascular lumen (marked with stars). 
The abluminal side of both the holes (inner part) and of the 
intraluminal filopodia-bearing endothelial cells (external 
part) showed positive laminin signal, as expected for a 
forming intraluminal pillar [14].
Taken together, these data show that, compared to high 
levels of VEGF alone, PDGF-BB co-delivery: (a) did 
not promote endothelial sprouting, but rather modulated 
VEGF-induced splitting angiogenesis; (b) anticipated the 
initiation of vascular enlargement; (c) did not affect the 
timing and frequency of transluminal pillar formation; and 
(d) accelerated the splitting of enlarged vessels and the 
completion of their remodeling.
Fig. 2  Absence of abluminal endothelial sprouting. Immunostaining 
with antibodies against endomucin (endothelial cells, green), laminin 
(basal lamina, red), and with DAPI (nuclei, blue) was performed on 
cryosections of TA and GC muscles 2 (a–c) and 3 days (d–f) after 
implantation with  VIPhigh myoblast clone. Enlarged vessels displayed 
no evidence of abluminal endothelial cell processes sprouting outside 
the basal lamina, but rather appeared pierced by numerous translu-
minal holes (white arrows in high-magnification panels in a and d) 
and displayed intraluminal vascular ridges (white arrowheads in high-
magnification panel in d). *Vascular lumen. n = 2 muscles per time 
point; scale bars = 20 µm in all panels
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PDGF‑BB limits the degree of vascular enlargement 
by high VEGF
We previously found that the switch between normal 
and aberrant angiogenesis correlates with a VEGF dose-
dependent increase in the size of initial vascular enlarge-
ments [9]. Therefore we investigated whether PDGF-BB 
affected the circumferential enlargement induced by 
VEGF. Normal capillaries in areas implanted with con-
trol cells had a very homogeneous size that was stable 
over time (Fig. 3a–d, e, f). Clonal myoblasts producing 
only PDGF-BB at the same level as the  VIPhigh cells 
(Phigh) were implanted as a further control, showing that 
PDGF-BB alone did not affect pre-existing vessels over 
7  days (Fig.  3a–d), causing no changes in either ves-
sel size or quantity (Fig. 3e, g). High VEGF caused an 
enlargement of the pre-existing capillaries starting after 
3 days and some of these vessels continued to grow in 
girth over time, failed to split and gave rise by 7 days to 
typical aberrant bulbous structures resembling angiomas, 
as evidenced both by the further increase in average diam-
eter by 4 and 7 days (Fig. 3e; day 3 = 17.0 ± 1.8 µm; day 
4 = 31.2 ± 4.7 µm and day 7 = 26.4 ± 2.6 µm) and by the 
appearance and persistence of a population of severely 
enlarged vessels > 30  µm in the diameter distribution 
analysis (Fig. 3f; day 4 = 18.8% and day 7 = 19.6%). On 
the other hand, PDGF-BB co-delivery caused vascular 
enlargements to start already by 2 days, with a size simi-
lar to that of high VEGF alone at 3 days (day 2  VIPhigh 
mean diameter = 14.8 ± 1.3 µm). However, these vessels 
did not undergo any further increase in girth by 3 days and 
by 4 days they were actually mostly already remodeled 
into networks of normal capillaries  (VIPhigh mean diam-
eter day 3 = 12.7 ± 2.2 µm, day 4 = 10.7 ± 0.3 µm and day 
7 = 7.0 ± 0.9 µm; Fig. 3e) of homogeneous size, with a 
diameter distribution similar to that of control samples by 
day 7, with no vessels > 30 µm (Fig. 3f).
The amount of induced angiogenesis was quantified by 
measuring vessel length density (VLD), defined as the total 
length of vessels in a given area independently of their diam-
eter. High VEGF alone did not cause a significant increase 
in VLD compared to controls or PDGF-BB alone at any 
time point (Fig. 3g), as growth took place mostly increas-
ing the size of vascular structures rather than contribut-
ing new vessels. However, PDGF-BB co-delivery caused 
VLD to be already doubled compared to controls by 3 days 
(Fig.  3g; Ctrl = 10.0 ± 0.5 and  VIPhigh = 23.3 ± 3.9  mm/
mm2; p < 0.05), reaching a sixfold increase by 7  days 
(Fig. 3g; Ctrl. = 11.1 ± 0.8 and  VIPhigh = 65.1 ± 6.2 mm/mm2; 
p < 0.0001).
Taken together, these results indicate that PDGF-BB co-
expression (a) limits the degree of vascular enlargement 
induced by high levels of VEGF; and (b) enables completion 
of vascular splitting leading to robust generation of normal 
capillary networks.
PDGF‑BB limits sustained endothelial proliferation 
by high VEGF and does not cause fibrosis
Next we asked whether PDGF-BB co-delivery could limit 
vascular enlargement by regulating endothelial proliferation 
induced by high VEGF. Immunostaining for Ki67 marks 
all proliferating cells in any phase of the cell cycle (G1-S-
G2-M), but not quiescent ones in G0 [15]. Quantification of 
Ki67+ endothelial cells showed that PDGF-BB alone did not 
affect endothelial proliferation at any time point (Fig. 4a–e). 
High VEGF alone caused markedly increased endothelial 
proliferation by day 3 (74.4 ± 6.5%) and this was sustained 
through day 7 (day 4 = 74.4 ± 6.1% and day 7 = 49.2 ± 3.9%; 
Fig. 4a–e), consistently with the kinetics of vascular enlarge-
ment described above (Fig. 3e). On the other hand, PDGF-
BB co-delivery caused endothelial proliferation to start 
already by day 2 (56.8 ± 12.9%), with no further increase 
by day 3 (53.7 ± 1.0%) and gradually subsiding by day 4 
(30.8 ± 12.0%) to reach almost complete quiescence by day 
7 (3.9 ± 0.6%; Fig. 4a–e). A comparison of proliferation at 
the 2 biologically equivalent stages defined above (Stage 
1 = first day of enlargement, and Stage 2 = second day of 
enlargement) showed that PDGF-BB co-delivery caused a 
moderate decrease in the number of proliferating endothe-
lial cells by about 15% during initial vascular enlargement 
(Fig. 4f). These results suggest that PDGF-BB co-expression 
can limit the degree of vascular enlargement and prevent 
aberrant angiogenesis both by moderately reducing the ini-
tial endothelial proliferation induced by high VEGF and 
rapidly abolishing it after day 4.
Since PDGF-BB is also a fibroblast mitogen [16], we 
investigated the possible induction of fibrosis. Co-staining 
for Ki-67 and the fibroblast-specific marker FSP1 [17] 
detected actively proliferating fibroblasts between mus-
cle fibers in the areas of implantation of Phigh myoblasts 
(Fig. 5a–c). However, fibroblast proliferation was transient 
between 4 and 7 days after myoblast implantation and by 28 
days had subsided (4 days = 109.5 ± 21.3 Ki-67 + fibroblasts/
field, 7 days = 41.5 ± 11.9 and 28 days = 1.7 ± 0.5; Fig. 5d), 
despite stable engraftment of the PDGF-BB-expressing 
myoblasts (Fig. 5e). In agreement with the lack of sustained 
fibroblast proliferation, no signs of fibrosis were detected in 
implanted muscles after 28 days (Fig. 5f).
PDGF‑BB prevents early pericyte loss induced 
by high VEGF
We have previously found that high VEGF causes loss of 
vascular pericytes [9, 10]. Therefore, we sought to determine 





of high VEGF on pericyte loss during the initial stages of 
vascular enlargement. Pericyte coverage of vascular struc-
tures was quantified after implantation of Vhigh and  VIPhigh 
myoblast clones at Stage 1 and 2 of enlargement (days 3/2 
and 4/3, respectively, for V and VIP) by measuring their 
maturation index, i.e., the ratio of the NG2+/CD31+ signal 
after immunostaining (Fig. 6  a–e). The results show that 
PDGF-BB co-expression prevented the loss of NG2 + peri-
cytes both at stage 1 and 2, maintaining a more than 50% 
greater maturation index by Stage 2 (Vhigh = 0.4 ± 0.1 vs. 
 VIPhigh = 0.7 ± 0.0; *p < 0.05; Fig. 5e). Therefore, the nor-
malization of aberrant vascular remodeling by PDGF-BB 
co-expression correlates with pericyte retention on the 
endothelial structures during the initial stages of VEGF-
induced enlargement.
PDGF‑BB does not affect microhemodynamic 
changes during VEGF‑induced non‑sprouting 
angiogenesis
Acute increases in both blood flow and shear stress have 
been shown to be potent triggers of splitting angiogenesis 
in microvascular networks and to rapidly initiate translu-
minal pillar formation without the need for growth factor 
delivery [18, 19]. Therefore, we investigated hemody-
namic parameters by repetitive intravital imaging of vas-
cular structures over time. Vhigh and  VIPhigh clones, as well 
as control myoblasts, were over-infected with a retroviral 
vector to stably produce the red fluorescent protein DsRed, 
to allow their direct visualization during in vivo imaging 
and were implanted into the panniculus carnosus mus-
cle of SCID mice in a dorsal skinfold chamber. Intravital 
fluorescence microscopy was performed once per day on 
day 0 immediately after cell implantation and from day 2 
(when vascular enlargements first appeared) up to day 4 
(when remodeling into normal capillaries by PDGF-BB co-
expression was almost complete). As expected, in muscles 
injected with control cells, only normal-sized capillaries 
were found that were unchanged over time (Fig. 7a–d). With 
high VEGF, pre-existing normal capillaries were still not 
affected at day 2 and displayed a diameter distribution simi-
lar to those in sites implanted with control cells (ctrl mean 
diameter = 8.2 ± 0.8 µm vs. Vhigh = 8.9 ± 0.4 µm. p = n.s.; 
Fig. 7e, f), but significant enlargement could be observed 
at days 3 and 4 (Fig. 7a–f), in agreement with the histologi-
cal data shown in Fig. 3. On the other hand, PDGF-BB co-
expression caused enlargement of pre-existing capillaries to 
start already by day 2 (Fig. 7a–d), but limited their size to 
a lesser degree of enlargement compared to VEGF alone at 
days 3 and 4, also confirming the histological findings above 
 (VIPhigh day 2 mean diameter = 16.5 ± 0.9 µm vs. Vhigh day 
3 = 32.4 ± 5.3 µm, p < 0.01;  VIPhigh day 3 = 17.8 ± 1.2 µm 
vs. Vhigh day 4 = 42.9 ± 3.3 µm, ***p < 0.0001; Fig. 7e, f). 
Quantification of hemodynamic stimuli revealed that high 
VEGF caused a marked reduction of both blood flow veloc-
ity and shear rate (BV and Y, respectively; Fig. 7g, h) at days 
3 and 4 compared to day 0, concomitantly with the marked 
vascular enlargement. Upon PDGF-BB co-expression blood 
velocity remained stable or decreased slightly during the 
vascular enlargement phase compared to day 0 (Fig. 7i), 
whereas shear rate also significantly diminished over days 2 
and 3 (Fig. 7j). These data suggest that a global reduction in 
shear stress accompanied the initiation of transluminal pil-
lar formation during VEGF-induced splitting angiogenesis, 
regardless of PDGF-BB co-expression.
PDGF‑BB limits VEGF signaling activation
The biological effects of VEGF are transduced by the 
receptor tyrosine kinase VEGF-Receptor 2 (VEGF-R2) 
[20]. In order to determine whether PDGF-BB could modu-
late VEGF activity, we assessed the relative activation of 
VEGF-R2 signaling output by measuring the expression of 
its specific target genes endocan (endothelial-specific mol-
ecule-1, Esm1) [21], Igfbp3 [22], and integrin β3 (Itgb3) 
[23]. The  VIPhigh clone, Vhigh clone, and control cells were 
injected in the tibialis anterior and gastrocnemius muscles 
of SCID mice. Gene expression was measured at stage 1 of 
vessel development, as defined above, when enlarged vessels 
started to appear in treated muscles (day 3 for Vhigh and day 
2 for  VIPhigh), as well as on the preceding day, defined as 
stage 0 immediately before the start of morphogenic events 
(day 2 for Vhigh and day 1 for  VIPhigh). This time point was 
added because at this stage vascular enlargements are not 
yet induced, but differences in VEGF-R2 signaling might be 
already established that lead to subsequent changes. In order 
to be sure that VIP-induced changes did not start earlier than 
day 2, muscles were analyzed 1 day after implantation with 
 VIPhigh cells (Fig. 8a–c). Capillaries in the areas of implan-
tation did not show any signs of circumferential enlarge-
ment, as vessel diameters were similar to those of the day 2 
Fig. 3  PDGF-BB co-expression limits the degree of vascular enlarge-
ment and induces robust normal angiogenesis. The time point labels 
(2, 3, 4, and 7 days) refer to all images and graphs in each column 
delimited by the red vertical lines. a–d Cryosections of TA and GC 
muscles implanted with Vhigh,  VIPhigh, Phigh, and control myoblasts 
were immunostained for CD31 (endothelial cells, green) and DAPI 
(nuclei, blue). b–c *Lumen of vascular enlargement and d of aberrant 
structure. e Values represent means (in µm) of individual measure-
ments in each sample ± SEM quantified in areas of myoblast implan-
tation at day 2, 3, 4, and 7 post-implantation. *p < 0.05, **p < 0.01, 
****p < 0.0001 by 1-way ANOVA. f Distribution of vessel diameters 
(in µm). g The amount of angiogenesis was quantified in the same 
areas: VLD vessel length density, expressed as millimeters of ves-
sel length per square millimeter of area of effect (mm/mm2). Data 
represent mean values  ±  SEM. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 by 1-way ANOVA. n = 3–5 independent muscles per 




Fig. 4  PDGF-BB co-expression limits endothelial proliferation. 
a–d Immunostaining with antibodies against CD31 (endothelial 
cells, green), Ki-67 (nuclei of proliferating cells, red), and with 
DAPI (nuclei, blue) was performed on cryosections of limb mus-
cles injected with Vhigh,  VIPhigh, and Phigh myoblast clones at day 2, 
3, 4, and 7 after myoblast implantation. The time point labels (2, 3, 
4, and 7 days) refer to all images and graphs in each column delim-
ited by the red vertical lines. a–c *Lumen of vascular enlargements 
and d of aberrant angioma-like structure. e–f Quantification of KI67 
marker in areas of effect showed that PDGFB co-expression reduced 
the total amount of proliferating endothelial cells compared to VEGF 
alone. Values represent means of individual measurements in each 
sample ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
by 1-way ANOVA. n = 3–5 independent muscles per each group, per 
time point. Scale bars = 20 µm in all panels
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control samples analyzed in Fig. 3e, f (mean = 5.2 ± 0.2 µm, 
median = 5.1 µm and 90th percentile = 7.7 µm). Further, we 
verified the possibility that in vivo VEGF expression by the 
 VIPhigh clone could be lost faster than by the Vhigh clone after 
implantation, which could be a confounding factor. ELISA 
quantification of VEGF protein in total muscles harvested 
from stages 0, 1, and 2 showed that, as expected, VEGF 
production was increased in all groups compared to control 
tissues. However, no loss of VEGF production could be seen 
in VIP-implanted muscles, which actually contained an even 
higher amount of VEGF than Vhigh samples at stage 0 and a 
similar one afterwards (Fig. 8d).
As shown in Fig. 8e–g, VEGF alone up-regulated the 
expression of all 3 target genes at stage 1 and Esm1 already 
at stage 0. On the other hand, in the presence of PDGF-BB, 
the signaling output of VEGF-R2 appeared significantly 
reduced compared to VEGF alone in all instances, as evi-
denced by significantly lower expression of all target genes 
at stage 1, as well as of Esm-1 also at stage 0.
Taken together, these findings suggest that PDGF-BB co-
expression limited the degree of enlargement of pre-existing 
capillaries by reducing the activation of VEGF-R2 signaling 
in the endothelium compared to VEGF alone.
Discussion
Taking advantage of a highly controlled myoblast-based 
gene delivery platform, here we found that PDGF-BB nor-
malizes aberrant angiogenesis by high levels of VEGF in the 
therapeutic target tissue of skeletal muscle by enabling effi-
cient vascular splitting and without inducing any sprouting. 
Hemodynamic parameters, such as blood velocity and shear 
stress, were not responsible for the effective completion 
of splitting. Rather, PDGF-BB co-delivery prevented the 
excessive enlargement of the pre-existing vessels, thereby 
enabling efficient and accelerated completion of vascular 
splitting into normal capillaries already by 4 days after factor 
delivery. Mechanistically, PDGF-BB moderated the degree 
of endothelial proliferation by limiting the VEGF-R2 signal-
ing output by similar VEGF doses.
It is important to recognize that angiogenesis in skel-
etal muscle can occur through two alternative mecha-
nisms: sprouting, which is mainly initiated by hypoxia dur-
ing ischemia [24] and splitting [14, 25]. Sprouting relies 
on the specification of specialized endothelial tip cells, 
which migrate into surrounding tissue and are followed by 
proliferating stalk cells [13]. On the other hand, splitting 
angiogenesis takes place without any abluminal endothe-
lial migration and comprises two different cellular mecha-
nisms: (1) intussusception, which relies on the formation of 
transluminal pillars through a zone of endothelial contact 
between invaginations of the opposite vessel walls [14]; and 
(2) longitudinal division, where exclusively endothelial filo-
podial ridges are extended intraluminally, without involve-
ment of the vessel wall [25]. Although it is not yet clear 
whether these two processes take place in different kinds 
of vessels, both lead to the generation of new vascular seg-
ments by vascular splitting rather than by abluminal sprout-
ing; for the sake of clarity, here we use the term “vascular 
splitting” to comprise both. Recently, we found that VEGF 
delivery to skeletal muscle at therapeutically relevant doses 
induces both normal and aberrant angiogenesis essentially 
without sprouting, but rather through a first stage of cir-
cumferential enlargement followed by longitudinal splitting 
[9]. Here, we now show that PDGF-BB co-delivery prevents 
aberrant vascular growth by high VEGF doses, converting 
it into normal microvascular networks, by modulating the 
same mechanism, i.e., by enabling efficient and accelerated 
vascular splitting, and not by switching to a sprouting mode 
of angiogenesis.
It has been previously shown that splitting angiogenesis 
in skeletal muscle can be initiated by changes in haemo-
dynamic factors [26]. In fact, sustained increases in blood 
flow and capillary shear stress, caused by chronic vasodila-
tion with the α-adrenergic inhibitor prazosin, induced capil-
lary growth by longitudinal division in rodent muscle [19, 
26–28]. Further, in the chicken chorioallantoic membrane 
(CAM) acute increases in flow and shear stress, achieved by 
clamping one of the major arterial side-branches upstream 
of the investigated areas, also caused many of the vascular 
bifurcations within these areas to undergo intussusceptive 
remodeling within 15–45 min [18]. On the other hand, here 
we found that high VEGF initially caused a marked global 
reduction of both blood flow velocity and shear stress, likely 
due to the marked enlargement of vessel diameters. How-
ever, PDGF-BB co-delivery did not change the trend of both 
hemodynamic parameters, which behaved similarly to the 
condition with VEGF alone. In agreement with these find-
ings, the frequency of pillar formation was not increased by 
PDGF-BB co-delivery compared to VEGF alone (Fig. 1i), 
suggesting that the increased efficiency of vascular split-
ting by PDGF-BB was not mediated through hemodynamic 
regulation.
The apparent discrepancy with the results of vasodila-
tion and clamping experiments can likely be explained by 
considering that in those conditions no growth factor was 
delivered and hemodynamic parameters were modified in 
the absence of any vascular enlargement. In contrast, the 
first effect of VEGF delivery to skeletal muscle is a cir-
cumferential enlargement of pre-existing vessels mediated 
by endothelial proliferation, which rather leads to a global 
decrease in flow and shear stress, as expected. Interestingly, 
recent data generated by 3D computational flow simulations 
based on in vivo calculations of haemodynamics parameters 





located in regions of comparatively lower shear stress and 
were spatially constrained by neighboring regions of higher 
flow and shear stress [29, 30]. Therefore, further insights 
into the fine regulation of pillar initiation by hemodynamic 
changes under therapeutically relevant conditions of growth 
factor delivery will require ad hoc investigations of intra-
vascular distribution of flow and shear in single vessels.
On the other hand, the key effect of PDGF-BB co-deliv-
ery was a limitation of the size of vascular enlargements 
induced by VEGF through a reduction in endothelial prolif-
eration. This observation is consistent with previous findings 
in developmental angiogenesis. In fact, the severe impair-
ment in pericyte recruitment caused by genetic ablation of 
the Pdgfb gene was shown to cause unabated endothelial 
proliferation, leading to the formation of aberrant microa-
neurysms and lethal hemorrhages [31]. Conversely, PDGF-
BB over-expression and increased pericyte recruitment were 
found to limit excessive tumor angiogenesis by inhibiting 
endothelial proliferation [32]. In the context of VEGF over-
expression, the observed limitation of endothelial prolif-
eration provides a plausible mechanism for the successful 
splitting into normal capillaries enabled by PDGF-BB co-
delivery, despite stimulation with high VEGF levels. In fact, 
we have previously found that the size of the initial vascu-
lar enlargements depends on the VEGF dose and, while in 
the smaller vessels induced by low VEGF pillar formation 
could proceed successfully and complete the splitting, in 
the larger-caliber structures induced by high VEGF pillar 
formation would start, but it could not be completed due 
to the excessive vascular diameter to bridge, leading to a 
failure to split and the continued circumferential growth of 
affected segments into angioma-like structures [9]. Here, 
we show that PDGF-BB co-delivery limits the size of initial 
enlargements caused by high VEGF, leading to diameters 
more similar to those induced by low VEGF alone [9]. These 
smaller-caliber vascular enlargements could successfully 
complete vascular splitting, even though the density of initial 
pillar formation was not increased compared to VEGF alone.
As previously described [9], enlarged vessels induced by 
high VEGF displayed a marked loss of pericyte coverage. 
In fact, VEGF at high doses can interfere with PDGF-BB 
signaling and negatively regulate pericyte recruitment [33] 
and we have previously found that endogenous PDGF-BB 
expression does not increase with increasing doses of VEGF 
delivery, leading to an imbalance between the two signaling 
pathways, loss of pericytes, and the switch to aberrant angio-
genesis [10]. Accordingly, PDGF-BB co-delivery could pre-
vent both pericyte loss and aberrant angiogenesis [10], in 
agreement with the findings reported here.
Pericytes establish complex regulatory functions on 
endothelial cells through both paracrine and juxtacrine 
signaling, among which the main pathways include Trans-
forming-Growth Factor-β, angiopoietin-1/-2, and ephrinB2/
EphB4 [34]. For example, TGF-β1 can inhibit endothelial 
proliferation and promote vessel stabilization [35], whereas 
ephrinB2 has been shown to regulate VEGF-R2 internaliza-
tion and its loss reduces VEGF-R2 signaling [36]. Interest-
ingly, we recently found that EphB4 stimulation by ephrinB2 
fine-tunes the degree of endothelial proliferation induced by 
specific VEGF doses through ERK1/2 modulation, thereby 
limiting the size of vessel enlargement and enabling success-
ful splitting [37]. As ephrinB2 is expressed by pericytes and 
requires cell-to-cell contact to engage and activate EphB4 
[38], PDGF-BB might regulate endothelial proliferation by 
promoting pericyte-endothelial crosstalk through ephrinB2/
EphB4 signaling, although a cell-autonomous action on 
endothelium cannot be excluded. Our data indicate that 
the limitation of VEGF-R2 signaling output by PDGF-BB 
co-expression has significant therapeutic implications, by 
efficiently preventing aberrant angiogenesis despite high 




Primary myoblasts isolated from C57BL/6 mice and trans-
duced to express the β-galactosidase marker gene (lacZ) 
from a retroviral promoter [39] were over-infected at high 
efficiency [40] with the retroviruses expressing murine 
 VEGF164 alone (V) or together with human PDGF-BB at a 
fixed ratio to each other from a bicistronic cassette through 
the encephalomyocarditis virus Internal Ribosomal Entry 
Site (IRES) as previously described (VIP: Vegf-Ires-
Pdgfb) [10]. A truncated version of CD8a (trCD8a) was 
co-expressed with VEGF from a similar bicistronic cas-
sette (V), or from a separate promoter (VIP), as a conveni-
ent cell surface marker of transduced cells, as described 
[11]. Single cells were isolated from the polyclonal 
Fig. 5  PDGF-BB over-expression does not cause fibrosis. a–c Immu-
nostaining with antibodies against FSP1 (fibroblasts, white), Ki-67 
(nuclei of proliferating cells, red), and with DAPI (nuclei, blue) was 
performed on cryosections of limb muscles injected with Phigh myo-
blasts at day 4, 7, and 28  days after myoblast implantation. Scale 
bars = 20  µm. d Quantification of the number of Ki-67 + fibroblast/
field of view in areas of effect showed no sustained fibroblast pro-
liferation by 4  weeks. Values represent means ± SEM. *p < 0.05, 
**p < 0.01 by 1-way ANOVA. e–f X-Gal staining (e) and Mas-
son trichrome staining (f) showed persistent engraftment of LacZ-
expressing myoblasts and the absence of fibrosis, respectively, after 
28 days. The panels on the right in e and f represent high-magnifica-
tion views of the areas marked by black boxes in the left panels. Scale 
bars = 500 µm in low-magnification panels (left) and 100 µm in high-




myoblast populations V, and VIP by FACS, based on 
their CD8 staining, using a Vantage SE cell sorter (Bec-
ton Dickinson, Basel, Switzerland). Single-cell isolation 
was confirmed visually and monoclonal populations of 
transduced myoblasts were expanded in culture to express 
specific and homogeneous levels of each factor, as previ-
ously described [6, 7, 10, 11]. All myoblast populations 
were cultured in 5%  CO2 on collagen-coated dishes, with 
a growth medium consisting of 40% F10, 40% DMEM 
low glucose (1000 mg glucose/l) (Sigma-Aldrich Che-
mie GmbH, Steinheim, Germany), and 20% fetal bovine 
serum (HyClone, Logan, UT) supplemented with 2.5 ng/
ml basic fibroblast growth factor (FGF-2) (Becton Dick-
inson, Basel, Switzerland), as described [41].
Myoblast implantation into mice
Cells were implanted into 8–24-week-old immunodeficient 
SCID CB.17 mice (Charles River Laboratories, Sulzfeld, 
Germany) in order to avoid an immunological response to 
β-galactosidase-expressing myoblasts and human Pdgfb. 
Animals were treated (a) in accordance with Swiss Federal 
guidelines for animal welfare and the study protocol was 
approved by the Veterinary Office of the Canton Basel-Stadt 
Fig. 6  Mural cell coverage. a–d Vessels induced by implantation of 
VHigh and  VIPHigh myoblast clones were immunostained with anti-
bodies against CD31 (endothelial cells, red), NG2 (pericytes, green), 
α-SMA (smooth muscle cells, cyan), and with DAPI (nuclei, blue) 
in cryosections of TA and GC muscles. a and c *Lumen of vascu-
lar enlargements. e The maturation index was quantified in areas 
implanted with each cell population at stage 1 and 2 of VEGF-
induced vascular enlargements. Co-expression of PDGF-BB caused a 
marked increase in mural cell coverage at both time points compared 
to high VEGF alone. Data represent mean values ± SEM; *p < 0.05 
by Kruskal–Wallis test. n = 3–6 independent muscles per each group; 
per time point. Scale bars = 20 µm in all panels
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Fig. 7  Microhemodynamics and vascular splitting. VHigh,  VIPHigh, 
and control myoblasts were implanted into the panniculus carnosus 
muscle of SCID mice in a dorsal skinfold chamber. The time point 
labels (0, 2, 3, and 4 days) refer to all images and graphs in each col-
umn delimited by the red vertical lines. a–d Intravital fluorescence 
microscopic images of capillaries in areas of myoblast implantation. 
e Values represent means (in µm) of individual measurements in each 
sample ± SEM quantified in areas of myoblast implantation at day 0, 
2, 3, and 4 post cell implantation. *p < 0.05, **p < 0.01, ***p < 0.001 
****p < 0.0001 by 1-way ANOVA. f The distribution of vessel diam-
eters (in µm) was quantified in areas of myoblast implantation. g–j 
Blood flow velocity (BV, in µm/s) and wall shear rate (γ, in  s−1) were 
quantified off-line concomitantly with onset of vascular enlarge-
ments. Data represent mean values ± SEM; *p < 0.05, *p < 0.05, 
***p < 0.001, ****p < 0.0001 by 1-way ANOVA or by Kruskal–Wal-
lis test. n = 2–6 independent muscles per each group; per time point. 
Scale bars = 100 µm in all panels
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(Basel, Switzerland) and (b) in accordance with the guide-
lines for the Care and Use of Laboratory Animals and the 
Institutional Animal Care and Use Committee (University 
of Rostock, Medical Faculty, Rostock, Germany). Myoblasts 
were dissociated in trypsin and resuspended at a concentra-
tion of  108 cells/ml in sterile PBS with 0.5% BSA. 1 × 106 
cells in 10 µl were implanted into the tibialis anterior (TA) 
and gastrocnemius (GC) muscles of the leg as previously 
described [7], or into the Panniculus Carnosus muscle, i.e., 
the thin subcutaneous muscle layer of murine skin, by using 
a syringe with a  291/2G needle.
Vascular casting
Vascular casts were prepared as previously described [42]. 
Briefly, the vasculature was perfused with a freshly prepared 
solution of PU4ii polymer (vasQtec, Zurich, Switzerland). 
One hour after perfusion, the samples were transferred to 
7.5% potassium hydroxide for dissolution of tissue, which 
was completed over 2–3 weeks. After washing, the casts 
were freeze-dried and glued onto the aluminum sample 
stabs. The samples were then sputtered with gold to a thick-
ness of 10 nm and examined in a Philips XL-30 SFEG scan-
ning electron microscope. TA muscle received 1 cell injec-
tion, whereas GC muscle received 2 cell injections (in both 
the medialis and lateralis portions). At least 7 areas of clear 
angiogenic effect in 3 entire legs per group per time point 
were analyzed.
Immunofluorescence tissue staining
Mice were anesthetized and the tissues were fixed by vas-
cular perfusion of 1% paraformaldehyde in PBS pH 7.4 
for 4 min under 120 mm/Hg of pressure, followed by 2 h 
of post-fixation in 0.5% paraformaldehyde in PBS pH 7.4. 
Entire tibialis anterior and gastrocnemius muscles excised 
from perfused mice were fixed for additional 2 h in 0.5% par-
aformaldehyde and then immersed overnight in 30% sucrose 
solution for cryoprotection before being embedded in OCT 
compound and frozen in freezing isopentane (Medite, Basel, 
Fig. 8  PDGF-BB co-expression reduces the activation of the 
VEGF signaling pathway. a–c Cryosections of TA and GC muscles 
implanted with  VIPhigh were immunostained for CD31 (endothelial 
cells, green) and DAPI (nuclei, blue). a 1  day after cell implanta-
tion the pre-existing vessels were not yet affected. b Values represent 
diameter mean (in µm) of individual measurements in each sam-
ple ± SEM quantified in areas of myoblast implantation. c Distribu-
tion of vessel diameters (in µm). n = 2 muscles. Scale bar = 20  µm. 
d Total VEGF protein content of muscle extracts was measured by 
ELISA (pg/mg of total protein). Data represent mean values ± SEM; 
*p < 0.05, **p < 0.01, ****p < 0.0001 by 1-way ANOVA. n = 5 inde-
pendent muscles per group, per time point. e–g In vivo expression of 
Esm1, Igfbp3, and Itgb3 genes, which are specifically induced by acti-
vation of VEGF-R2 signaling, was quantified in calf muscles at day 
1, 2, and 3 after injections of control,  Vhigh, and  VIPhigh myoblasts. 
PDGF-BB co-expression significantly reduced the signaling out-
put downstream of VEGF-R2, despite similar or even higher levels 
of VEGF protein in the tissues. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 by 1-way ANOVA. n = 4–6 independent muscles per 
group, per time point
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Switzerland). Tissue sections were then stained with X-gal 
(20 µm sections) to reveal myoblast engraftment or with 
H&E (14 µm sections) as described previously [39, 40]. In 
addition, the presence of fibrosis was examined with Mas-
son trichrome staining (Réactifs RAL, Martillac, France) 
according to manufacturer’s instructions. Immunofluores-
cence staining was performed on 20-µm-thick frozen sec-
tions of muscles tissues, cut along the longitudinal axis. The 
following primary antibodies and dilutions were used: rat 
anti-CD31 (clone MEC 13.3, BD Biosciences, Basel, Swit-
zerland) at 1:100; rat anti-endomucin (clone V.7C7, Santa 
Cruz Biotechnology, Santa Cruz, CA); mouse anti-Mts1 
(FSP-1) (clone X9-7, Santa Cruz Biotechnology, Santa Cruz, 
CA) at 1:200; mouse anti-α-SMA (clone 1A4, MP Biomedi-
cals, Basel, Switzerland) at 1:400; rabbit anti-NG2 (Chemi-
con International, Hampshire, UK) at 1:200; chicken anti-
laminin (Abcam, Cambridge, UK); rabbit anti-Ki67 (Abcam, 
Cambridge, UK) at 1:100; rat anti-Ki67 (clone SolA15, Inv-
itrogen, Basel, Switzerland) at 1:200. Fluorescently labeled 
secondary antibodies (Invitrogen, Basel, Switzerland) were 
used at 1:200.
Vessel analyses
Vessel length density (VLD) and diameters were quantified 
in fluorescently immunostained cryosections as previously 
described [7]. Briefly, VLD was measured in at least 3 fields/
section per muscle, cut at 100–150 µm of distance from each 
other (n = 2–5 muscles/group) by tracing the total length of 
vessels in the field and dividing it by the area of the fields.
Vessel diameters were measured in fluorescently immu-
nostained sections as described [7]. Briefly, 10–20 fields/
muscle (n = 2–5 muscles/group) were analyzed, measur-
ing a total of 100 up to 500 vessel diameter per time point 
by overlaying captured microscopic images with a square 
grid. Squares were randomly chosen, and the diameter of 
each vessel (if any) in the center of selected squares was 
measured. To avoid selection bias, the shortest diameter 
in the selected vascular segment was systematically meas-
ured. Ki67+ endothelial cells were quantified as a percent-
age of all endothelial cells in analyzed vascular structures: 
400–3500 total endothelial cells were counted per condi-
tion and per time point taking 5–15 random fields of view/
sample with a clear angiogenic effect (n = 3–5 muscles/
group). Ki67+ fibroblasts were quantified in areas of myo-
blast implantation, detected by LacZ staining: 40–1900 total 
fibroblasts were counted per time point and condition taking 
5–10 random fields of view/sample (n = 4 muscles/group). 
Fluorescence images were acquired as Z-Stack with ×40 
objective on a Carl Zeiss LSM710 3-laser scanning con-
focal microscope (Carl Zeiss, Feldbach, Switzerland). 3-D 
immunofluorescence images were generated by using Imaris 
7.6.5 software (Bitplane, Zürich, Switzerland). All image 
measurements were performed with LSM software Zen 2010 
(Carl Zeiss, Feldbach, Switzerland) or with cellSens soft-
ware (Olympus, Volketswil, Switzerland). The quantifica-
tion of pericyte coverage was performed on sections of leg 
muscles after immunostaining for endothelium (CD31) and 
pericytes (NG2). The CD31- and NG2-positive areas were 
separately subjected to threshold processing. The areas occu-
pied by their respective signals were measured by Imaris 
7.6.5 software (Bitplane, Zürich, Switzerland) on Z-Stack, 
1024 × 1024, 8 bit Fluorescence images acquired with ×40 
objective on a Carl Zeiss LSM710 3-laser scanning confo-
cal microscope (Carl Zeiss, Feldbach, Switzerland), and the 
pericyte coverage index was calculated as the ratio between 
the two values.
Dorsal skinfold chamber and vessel analyses
The dorsal skinfold chamber was prepared as originally 
described in mice [43]. Mice were anesthetized by an intra-
peritoneal injection of ketamine (90 mg/kg bw) and xyla-
zine (25 mg/kg bw) and placed on a 37 °C heating pad. 
Briefly, a double skin layer on the back of the animal was 
implanted between two symmetric titanium frames. One 
skin layer was then completely removed in a circular area 
of 15 mm in diameter, and the remaining layers (consist-
ing of striated skin muscle, subcutaneous tissue, and skin) 
were covered with a glass coverslip incorporated into one of 
the titanium frames. Animals showed no signs of discom-
fort or changes of sleeping and feeding habits. To reduce 
surgical trauma-associated deterioration of the chamber 
microcirculation, mice were allowed a recovery period of 
2 days after implantation of the chamber. After injection 
of 0.1 ml fluorescein isothiocyanate (FITC)-labeled dextran 
(2%; molecular weight 150 kDa; Sigma-Aldrich, Munich, 
Germany) into the retro-orbital venous plexus and subse-
quent circulation for 30 s, microcirculation of the striated 
muscle tissue was visualized by intravital fluorescence 
microscopy using a Zeiss microscope (Axiotech vario; 
Zeiss, Jena, Germany). The microscopic procedure was per-
formed at a constant room temperature of 21–23 °C. The 
epi-illumination setup included a 100-W HBO mercury lamp 
(Osram GmbH, Munich, Germany) and a blue filter sys-
tem (450–490/ > 520 nm excitation/emission wavelength). 
Microscopic images were recorded by a charge-coupled 
device video camera (FK 6990 IQ-S; Piper, Schwerte, Ger-
many) and stored on videotapes (Fujifilm video cassette; 
Fuji Magnet-ics GmbH, Düsseldorf, Germany). Microcir-
culatory variables were quantified off-line by analysis of 
the aforementioned videotaped images using a computer-
assisted image analysis system (CapImage; Zeintl Software, 
Heidelberg, Germany). Functional Capillary Density, i.e., 
the length of all perfused capillaries per region of inter-
est was normalized by the initial values measured per each 
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experimental condition at day 0 immediately after myoblast 
implantation. Measurement of vascular wall shear rates (Y) 
was based on the Newtonian definition γ = 8 × v/ds−1, where 
d represents the individual inner vessel diameter and v rep-
resents the red blood cell centerline velocity divided by 1.6 
according to the Baker–Wayland factor to correct the para-
bolic velocity profile in microvessels [44] (n = 2–5 muscles/
group/time point).
RNA extraction and quantitative real‑time PCR
For RNA extraction from total muscles, freshly harvested 
tissue was frozen in liquid nitrogen and disrupted using a 
Qiagen TissueLyser (Qiagen, Basel, Switzerland) in 1 ml 
TRIzol reagent (Invitrogen, Basel, Switzerland) for 100 mg 
of tissue. Total RNA was isolated from lysed tissues with 
the mirVANA Kit (Life Technologies, Zug, Switzerland) 
according to manufacturer’s instruction. RNA was reverse 
transcribed into cDNA using the OmniScript Reverse 
Transcription kit (Qiagen, Basel, Switzerland) at 37 °C for 
60 min. Quantitative Real-Time PCR (qRT-PCR) was per-
formed on an ABI 7500 Real-Time PCR system (Applied 
Biosystems, Basel, Switzerland). Expression of genes of 
interest was determined using the following TaqMan Gene 
Expression assays (Applied Biosystems, Basel, Switzer-
land) according to manufacturer’s instructions: mouse 
Gapdh (Mm03302249_g1), mouse Esm1 (Mm00469953_
m1), mouse Igfbp3 (Mm01187817_m1), and mouse Itgb3 
(Mm00443980_m1). The cycling parameters were 50 °C 
for 2 min, followed by 95 °C for 10 min, and 40 cycles of 
denaturation at 95 °C for 15 s and annealing/extension at 
60 °C for 1 min. Reactions were performed in triplicate for 
each template, averaged, and normalized to expression of 
the Gapdh housekeeping gene at each specific correspond-
ing time point.
VEGF protein and total RNA assay in muscle tissue
Whole fresh mouse muscles were disrupted using a Qiagen 
TissueLyser (Qiagen, Hombrechtikon, Switzerland) in 1 ml 
of PBS + 1% Triton X-100 for 100 mg of tissue, supple-
mented with Complete Protease Inhibitor Cocktail (Roche 
Diagnostics, Rotkreuz, Switzerland), which was non-dena-
turing for proteins. After centrifugation, lysates were used 
for VEGF protein quantification by ELISA analysis (R&D 
Systems Europe, Abingdon, UK) normalized for the for total 
extracted protein/muscle quantified by using the Advanced 
Protein Assay (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). (n = 5 muscles per group per time point).
Statistical analysis
Data are presented as mean ± standard error. The signifi-
cance of differences was assessed with the GraphPad Prism 
7.03 software (GraphPad Software). The normal distribution 
of all data sets was tested by D’Agostino and Pearson or 
Shapiro–Wilk and, depending on the results, multiple com-
parisons were performed with the parametric 1-way analy-
sis of variance (ANOVA) followed by the Tukey or Sidak 
test for multiple comparisons, or with the non-parametric 
Kruskal–Wallis test followed by Dunn’s post-test, while 
single comparisons were analyzed with the non-parametric 
Mann–Whitney test. Gene expression data representing fold-
changes vs control, which are asymmetrically distributed, 
were first normalized by logarithmic transformation and then 
analyzed by 1-way ANOVA followed by the Sidak test for 
multiple comparisons. Vessel diameter values were first nor-
malized by log2-transformation and then analyzed by 1-way 
ANOVA followed by the Tukey test for multiple compari-
sons. p < 0.05 was considered statistically significant.
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